MOR00208
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for MOR00208, covering 2018-02-22 to 2025-12-15. Get the full timeline:
Most recent: Clinical Trial Update: Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL [Phase 2]